

1 **Understanding olfactory dysfunction in COVID-19: Expression of ACE2, TMPRSS2 and**

2 **Furin in the nose and olfactory bulb in human and mice**

3

4 **Short Summary:** ACE2, TMPRSS, and Furin expression patterns suggest sensorineural

5 dysfunction without olfactory neuronal damage in COVID-19-associated anosmia.

6

7 Rumi Ueha^{1*}, M.D., Ph.D.; Kenji Kondo¹ M.D., Ph.D.; Ryoji Kagoya¹ M.D., Ph.D.; Shigeyuki

8 Shichino², Ph.D.; Satoshi Ueha², Ph.D.; and Tatsuya Yamasoba M.D., Ph.D.

9

10 1. Department of Otolaryngology and Head and Neck Surgery, Faculty of Medicine, the

11 University of Tokyo, Tokyo, Japan

12 2. Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute

13 for Biomedical Sciences, Tokyo University of Science, Chiba, Japan

14

15 **Correspondence to:** Rumi Ueha

16 Department of Otolaryngology and Head and Neck Surgery, Faculty of Medicine, the University

17 of Tokyo, Tokyo, Japan, 113-8655

1 E-mail: ruu1025@yahoo.co.jp

2 Tel: +81-3-3815-5411, Fax: +81-3-3814-9486

3

4

5

6

1 **Abstract**

2 Background: Anosmia is a frequent symptom in coronavirus disease 2019 (COVID-19) patients
3 that generally resolves within weeks. In contrast, the anosmia caused by other upper respiratory
4 infections affects a small proportion of patients and may take months to resolve or never resolve.
5 The mechanisms behind COVID-19-induced olfactory dysfunction remain unknown. Here, we
6 address the unique pathophysiology of COVID-19-associated olfactory dysfunction.

7

8 Methods: The expression of ACE2 (virus binding receptor) and TMPRSS2 and Furin (host cell
9 proteases facilitating virus entry) was examined in the nasal mucosa, composed of respiratory
10 mucosa (RM), olfactory mucosa (OM), and olfactory bulb (OB) of mouse and human tissues
11 using immunohistochemistry and gene analyses.

12

13 Results: Co-expression of ACE2, TMPRSS2, and Furin was observed in the RM and in the OM,
14 especially in the supporting cells of the olfactory epithelium and the Bowman's glands. Notably,
15 the olfactory receptor neurons (ORNs) in the OM were positive for ACE2 but almost negative for
16 TMPRSS2 and Furin. Cells in the OB expressed ACE2 strongly and Furin weakly, and did not
17 express TMPRSS2. All three gene expressions were confirmed in the nasal mucosa and OB.

1

2 Conclusions: ACE2 was widely expressed in all tissues, whereas TMPRSS2 and Furin were
3 expressed only in certain types of cells and were absent in the ORNs. These findings, together
4 with clinical reports, suggest that COVID-19-related anosmia occurs mainly through
5 sensorineural and central dysfunction and, to some extent, conductive olfactory dysfunction. The
6 expression of ACE2, but not TMPRSS2 or Furin, in ORNs may explain the early recovery from
7 anosmia.

1 **Introduction**

2 The recent international spread of the coronavirus disease 2019 (COVID-19) caused
3 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a serious health
4 emergency. COVID-19 usually begins with simple respiratory symptoms such as fever, sore
5 throat, and cough for 2–3 days (1, 2). Notably, chemosensitive disorders, such as loss or decline
6 of smell (anosmia or hyposmia), and loss of taste (ageusia or dysgeusia), have been repeatedly
7 reported as unique clinical features of COVID-19 (3, 4), and are now considered typical
8 symptoms of the early stages of SARS-CoV-2 infection (4, 5). A recent published meta-analysis
9 demonstrated a 52.73% prevalence of olfactory dysfunction among 1,627 COVID-19 patients
10 (6). Specifically, a high rate of anosmia (complete loss of smell) is well documented (3, 5, 7, 8).
11 In contrast, only a small proportion (up to 20%) of patients with upper respiratory infection (URI)
12 exhibits olfactory dysfunction (9). The prognosis of olfactory dysfunction due to URI is generally
13 poor, with the majority of patients showing no or slight recovery within a few months (10),
14 whereas olfactory dysfunction in COVID-19 patients resolves relatively rapidly, with a reported
15 duration of 1 to 4 weeks (3, 8, 11-13). In a cohort study of COVID-19 patients with olfactory
16 dysfunction, loss of smell was reported to be the first symptom in 27% of patients (12). Thus, the
17 clinical features of COVID-19-associated olfactory dysfunction are significantly different from

1 those found in patients with common URIs, which are caused by viruses such as rhinovirus,
2 picornavirus, and parainfluenza virus (9, 14-16).

3 SARS-CoV-2 host cell entry depends on several factors: the binding of viral spike
4 proteins to the cellular receptor angiotensin-converting enzyme 2 (ACE2) (17-19), spike protein
5 cleavage by the host cell enzyme Furin (19-21), and spike protein priming by host cell proteases
6 such as transmembrane protease serine 2 (TMPRSS2) (19, 22). Thus, the high expression of
7 ACE2, TMPRSS2, and Furin is thought to enhance SARS-CoV-2 entry as well as clinical
8 symptoms.

9 Based on its histological components and functions, the nasal mucosa is divided into
10 the respiratory mucosa (RM) and the olfactory mucosa (OM). The RM consists of various types
11 of epithelial cells, including ciliated columnar and goblet cells. The OM serves olfaction and
12 consists of the olfactory epithelium (OE) and subepithelial tissues (23). The degree of olfaction
13 is closely related to the number of mature olfactory receptor neurons (ORNs) in the OE. The
14 olfactory system consists of peripheral compartments such as the OM, and central structures
15 such as the olfactory bulb (OB) and the piriform/entorhinal cortex (24).

16 To date, the expression of *ACE2* (25, 26) and *TMPRSS2* (26), but not *Furin*, has been
17 reported in the nasal epithelium. However, the histological evaluation of their expression has

1 been limited; only one study reported the expression of ACE2 and TMPRSS2 proteins in the
2 nasal mucosa and respiratory sinus, although it did not demonstrate immunostaining images of
3 the nasal mucosa (27). In the present study, we sought to elucidate the mechanisms underlying
4 olfactory dysfunction and the pathogenesis of high viral load in the upper airways of COVID-19
5 patients. Toward that aim, we investigated the expression of ACE2, TMPRSS2, and Furin in the
6 RM, OM, and OB of human and mouse tissues.

7

8 **Methods**

9 *Experimental samples*

10 Animal tissue samples were all obtained from the mice examined in the previous
11 published studies (23, 28), because purchasing new animals had been prohibited in our facility
12 due to the epidemic spread. The samples from 6 eight-week-old male C57BL/6 mice (23) and
13 an eight-week-old- male Sprague Dawley rat (28) were used, and the following paraffin-
14 embedded tissues were collected; the RM area and OM area of the nose, the OB area, and the
15 kidney and prostate for positive controls of immunostaining (Figure 1A). Human tissues were
16 obtained from patients undergoing surgery for the treatment of chronic sinusitis or olfactory
17 neuroblastoma. These included the OM (n = 3), the middle turbinate (n = 5), and inferior turbinate

1 (n = 6); the latter two were used for the evaluation of the RM. Routine morphology was evaluated
2 in haematoxylin and eosin-stained sections by a qualified pathologist and otolaryngologists.
3 Tissue evaluation was performed only in the parts characterized as non-diseased. All
4 experiments were conducted in accordance with institutional guidelines and with the approval of
5 the Animal Care and Use Committee of the University of Tokyo (No. P14-051, P15-115) and of
6 the Research Ethics Committee of the Graduate School of Medicine and Faculty of Medicine,
7 the University of Tokyo, Japan (12009, 2019073NI). Since archived specimens were used,
8 written informed consent was waived.

9

10 *Histological analyses*

11 To detect the expressions of ACE2 and TMPRSS2 in the RM, OM, and OB, histological
12 analyses were performed by immunostaining. Four- μ m-thick serial paraffin sections were
13 deparaffinized in xylene and dehydrated in ethanol before immunostaining. Prior to
14 immunostaining, deparaffinized sections were treated with 3% hydrogen peroxide to block
15 endogenous peroxidase activity and were incubated in Blocking One (Nacalai Tesque, Kyoto,
16 Japan) to block non-specific immunoglobulin binding. After antigen activation, primary antibodies
17 against ACE2 (1:300 dilution; rabbit monoclonal, Abcam, ab108252; Cambridge, UK),

1 TMPRSS2 (1:1000 dilution; rabbit monoclonal, Abcam, ab92323; Cambridge, UK), Furin (1:100
2 dilution; rabbit monoclonal, Abcam, ab183495; Cambridge, UK) , and PGP9.5 for a neuronal
3 marker (1:500 dilution; guinea pig polyclonal, Abcam, ab10410; Cambridge, UK) were detected
4 with peroxidase conjugated appropriate secondary antibodies and a diaminobenzidine substrate.
5 The mouse kidney and rat prostate were stained for positive controls for ACE2 and for TMPRSS2
6 and Furin, respectively (Figure 1B). All samples were stained under the same condition and
7 protocol as the positive control staining. Images of all sections were captured using a digital
8 microscope camera (Keyence BZ-X700) with 4x, 10x, 20x, and 40x objective lenses.

9

10 *Gene expression analyses*

11 Our previous DNA microarray data from the nasal mucosa and OB (NCBI Gene
12 Expression Omnibus database under the series number GSE 103191, 150694) was used to
13 examine the expressions of *ACE2*, *TMPRSS2*, and *Furin*. The expression levels of each gene
14 were normalized against the expression level of *Rps3* (encoding ribosomal protein S3) in each
15 sample.

16

17 **Results**

1 The immunohistological data is summarized in Table 1. ACE2, TMPRSS2, and Furin
2 were present in human and mouse nasal mucosa and in mouse OB, though the expression
3 pattern of ACE2, TMPRSS2, and Furin varied among tissues. Remarkably, co-expression of
4 ACE2, TMPRSS, and Furin was detected in the supporting cells and Bowman's glands of the
5 OM, and diffusely in the RM, but not in the ORNs of the OM or in the OB.

6 In mouse RM, ACE2, TMPRSS2, and Furin were all strongly expressed in the
7 cytoplasm of respiratory epithelial cells and in the subepithelial glands (Fig. 1a, b). ACE2 and
8 TMPRSS2 were highly co-expressed in the RE. The villous brush border of the respiratory
9 columnar epithelium was strongly positive for TMPRSS2 expression. In addition, moderate
10 cytoplasmic staining for TMPRSS2 and Furin was observed in the subepithelial tissue (Fig. 2a,
11 b). In OM, only supporting cells and Bowman's glands expressed ACE2, TMPRSS2, and Furin.
12 The olfactory nerve bundles were moderately positive for ACE2 and TMPRSS2. Notably, all cells
13 in the OE, including supporting cells, ORNs, and basal cells, were positive for ACE2, while the
14 ORNs were negative for TMPRSS2 and Furin (Fig. 2c, d). In the OB, there were no cells
15 expressing ACE2, TMPRSS2, and Furin simultaneously (Fig. 3a-c). ACE2 positive cells were
16 detected in the glomerular layer, mitral cell layer, and granule cell layer, but those cells were
17 negative for TMPRSS2. On the other hand, some cells in the glomerular layer and mitral cells

1 were positive for Furin. TMPRSS2 was strongly expressed in cells of the OB core (Fig. 3b).

2 To reinforce the above histological results, we investigated *Ace2*, *Tmprss2*, and *Furin*
3 gene expression in mouse nasal mucosa and OB. Using the database from the previous
4 study(24), the expression of the three genes was confirmed in the nasal mucosa and OB (Fig.
5 3d).

6 In human nasal mucosa, the PGP9.5 antibody clearly visualized the OE containing
7 olfactory neurons. ACE2 was localized in PGP9.5 positive ORNs. In addition, while Furin was
8 not present in the OE, TMPRSS2 was weakly expressed in the apical layer of the OE. (Fig. 4a,
9 b). In the RM, ACE2, TMPRSS2, and Furin were widely co-expressed in the epithelium (Fig. 4c,
10 d). These findings were basically identical to those found in mouse tissues.

11

12 **Discussion**

13 COVID-19 causes numerous clinical symptoms, including a deteriorated sense of taste
14 and smell, respiratory, and digestive disorders (3, 4, 29). Anosmia, the loss of smell, is a unique
15 clinical feature observed in the early stages of COVID-19. Unlike the anosmia caused in other
16 URIs, the COVID-19 anosmia occurs in most patients and resolves rather quickly. SARS-CoV-2
17 cell entry is dependent on the expression of the host cell proteins ACE2, TMPRSS2, and Furin.

1 Since the expression of these proteins in the nasal mucosa remains rather elusive, we
2 investigated the expression of ACE2, TMPRSS2, and Furin in the RM, OM, and OB of human
3 and mouse tissues to elucidate the mechanisms underlying olfactory dysfunction and high viral
4 load in the upper airways of COVID-19 patients.

5 The results of the present study explain why olfaction is frequently impaired in COVID-
6 19 patients. We observed the immunolocalization of ACE2, TMPRSS2, and Furin in the nasal
7 tissue and the OB, which are considered to play a pivotal role in the manifestation of the olfactory
8 dysfunction induced by SARS-CoV-2 infection. Histologically, ACE2, TMPRSS, and Furin were
9 co-expressed in the supporting cells and Bowman's glands of the OM as well as in the RM, but
10 not in the ORNs of the OM or the OB. *Ace2*, *Tmprss2*, and *Furin* gene expression was confirmed
11 in the nasal mucosa and the OB, supporting the immunohistochemical findings.

12 Olfactory dysfunction is defined into three types according to the anatomical location;
13 conductive, sensorineural, and central (30). Conductive dysfunction results from the blockage of
14 odorant airflow to the OE. Sensorineural dysfunction is caused by damage of the ORNs and the
15 olfactory nerve, impaired olfactory adaptation, and/or odorant transport. The supporting cells and
16 the Bowman's glands are involved in olfactory adaptation and the neurotrophic and physical
17 support of the OE (31-33). Thus, if the function of the supporting cells and the Bowman's glands

1 is deteriorated, odor adaptation is impaired, and subsequently, sensorineural dysfunction occurs.
2 Central dysfunction occurs with the damage of olfactory processing pathways in the central
3 nervous system (30). Based on the present histological results, we suggest that SARS-CoV-2
4 mainly induces sensorineural olfactory dysfunction without olfactory neuronal damage.

5 In the olfactory mucosa, co-expression of ACE2, TMPRSS2, and Furin in the supporting
6 cells and the Bowman's glands suggests that COVID-19 may induce the deterioration of mucus
7 production and OE support, resulting in impaired odor adaptation and transduction. Moreover,
8 co-expression of ACE2 and TMPRSS2 in the olfactory nerve bundle implies that odor
9 transduction may be impaired through neuronal dysfunction. It is unlikely that SARS-CoV-2
10 directly damages the ORNs in the OM because the ORNs expressed ACE2, but not TMPRSS2
11 or Furin. Furthermore, the severe damage of ORNs would not explain the early recovery of
12 olfaction observed in COVID-19 patients with anosmia, since the turnover rate of ORNs is
13 approximately 30 days (34). The co-expression of ACE2 and Furin in the mitral cells of the OB,
14 which have large cell bodies and secondary dendrites, suggests that central olfactory dysfunction
15 may occur as a result of synaptic inhibition from the ORNs to the olfactory bulb. Although most
16 COVID-19 patients recover from olfactory dysfunction, some patients have not recovered their
17 olfaction after several months (8). Those COVID-19 patients with prolonged olfactory dysfunction

1 may have suffered from continuing sensorineural and central olfactory dysfunction.

2 Considering the high expression of ACE2, TMPRSS2, and Furin in the RE and the
3 subepithelial glands, SARS-CoV-2 possibly induces conductive olfactory dysfunction through
4 hypersecretion and goblet cell hyperplasia (14, 35). In fact, a significant number of COVID-19
5 patients suffer from nasal obstruction and rhinorrhea(3), but the olfactory symptoms due to
6 conductive olfactory dysfunction may fluctuate and mostly resolve completely. In addition,
7 considering that a certain proportion of COVID-19 patients with hyposmia and anosmia did not
8 exhibit nasal obstruction or rhinitis symptoms(3, 36), the contribution of conductive olfactory loss
9 may be limited. However, some COVID-19 patients with prolonged olfactory dysfunction possibly
10 suffer from continuing sensorineural and central olfactory dysfunction. Future studies are needed
11 for clinical evaluation with long-term-follow-up. As for limitations of the present study, the
12 evaluation was performed on mice and some patients with olfactory neuroblastoma which may
13 not correctly reflect the backgrounds of SARS-CoV-2 infection. Future clinical case studies and
14 autopsy studies might strengthen this study.

15 In conclusion, the present study demonstrates high expression of ACE2, TMPRSS2,
16 and Furin in the nasal mucosa including the SPs and Bowman's glands, and in OB. The
17 expression pattern suggests that COVID-19 associated olfactory dysfunction is mainly

1 sensorineural and central, and to some extent, conductive. The expression of ACE2, but not

2 TMPRSS2 or Furin, in ORNs may explain the early recovery from anosmia.

3

4

5

1 **References**

- 2 1. C. Huang *et al.*, Clinical features of patients infected with 2019 novel coronavirus in
3 Wuhan, China. *Lancet* **395**, 497 (Feb 15, 2020).
- 4 2. X. Huang, F. Wei, L. Hu, L. Wen, K. Chen, Epidemiology and Clinical Characteristics of
5 COVID-19. *Archives of Iranian medicine* **23**, 268 (Apr 1, 2020).
- 6 3. J. R. Lechien *et al.*, Olfactory and gustatory dysfunctions as a clinical presentation of
7 mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European
8 study. *European archives of oto-rhino-laryngology : official journal of the European*
9 *Federation of Oto-Rhino-Laryngological Societies*, (Apr 6, 2020).
- 10 4. L. A. Vaira *et al.*, Objective evaluation of anosmia and ageusia in COVID-19 patients:
11 Single-center experience on 72 cases. *Head & neck*, (Apr 27, 2020).
- 12 5. J. Krajewska, W. Krajewski, K. Zub, T. Zatonski, COVID-19 in otolaryngologist practice:
13 a review of current knowledge. *European archives of oto-rhino-laryngology : official*
14 *journal of the European Federation of Oto-Rhino-Laryngological Societies*, (Apr 18,
15 2020).
- 16 6. J. Y. Tong, A. Wong, D. Zhu, J. H. Fastenberg, T. Tham, The Prevalence of Olfactory and
17 Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis.

- 1 *Otolaryngology--head and neck surgery : official journal of American Academy of*
2 *Otolaryngology-Head and Neck Surgery*, 194599820926473 (May 5, 2020).
- 3 7. B. Russell *et al.*, Anosmia and ageusia are emerging as symptoms in patients with
4 COVID-19: What does the current evidence say? *Ecancermedicalscience* **14**, ed98
5 (2020).
- 6 8. C. Hopkins, P. Surda, E. Whitehead, B. N. Kumar, Early recovery following new onset
7 anosmia during the COVID-19 pandemic - an observational cohort study. *Journal of*
8 *otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de*
9 *chirurgie cervico-faciale* **49**, 26 (May 4, 2020).
- 10 9. A. M. Seiden, Postviral olfactory loss. *Otolaryngologic clinics of North America* **37**, 1159
11 (Dec, 2004).
- 12 10. M. Yamagishi, M. Fujiwara, H. Nakamura, Olfactory mucosal findings and clinical course
13 in patients with olfactory disorders following upper respiratory viral infection. *Rhinology*
14 **32**, 113 (Sep, 1994).
- 15 11. C. H. Yan, F. Faraji, D. P. Prajapati, C. E. Boone, A. S. DeConde, Association of
16 chemosensory dysfunction and Covid-19 in patients presenting with influenza-like
17 symptoms. *International forum of allergy & rhinology*, (Apr 12, 2020).

- 1 12. R. Kaye, C. W. D. Chang, K. Kazahaya, J. Brereton, J. C. Denny, 3rd, COVID-19
2 Anosmia Reporting Tool: Initial Findings. *Otolaryngology--head and neck surgery* :
3 *official journal of American Academy of Otolaryngology-Head and Neck Surgery*,
4 194599820922992 (Apr 28, 2020).
- 5 13. A. R. Sedaghat, I. Gengler, M. M. Speth, Olfactory Dysfunction: A Highly Prevalent
6 Symptom of COVID-19 With Public Health Significance. *Otolaryngology--head and neck*
7 *surgery : official journal of American Academy of Otolaryngology-Head and Neck*
8 *Surgery*, 194599820926464 (May 5, 2020).
- 9 14. M. Suzuki *et al.*, Identification of viruses in patients with postviral olfactory dysfunction.
10 *The Laryngoscope* **117**, 272 (Feb, 2007).
- 11 15. D. A. Deems *et al.*, Smell and taste disorders, a study of 750 patients from the University
12 of Pennsylvania Smell and Taste Center. *Archives of otolaryngology--head & neck*
13 *surgery* **117**, 519 (May, 1991).
- 14 16. W. S. Cain, J. F. Gent, R. B. Goodspeed, G. Leonard, Evaluation of olfactory dysfunction
15 in the Connecticut Chemosensory Clinical Research Center. *The Laryngoscope* **98**, 83
16 (Jan, 1988).
- 17 17. W. Li *et al.*, Angiotensin-converting enzyme 2 is a functional receptor for the SARS

- 1 coronavirus. *Nature* **426**, 450 (Nov 27, 2003).
- 2 18. F. Wu *et al.*, A new coronavirus associated with human respiratory disease in China.
3 *Nature* **579**, 265 (Mar, 2020).
- 4 19. S. Lukassen *et al.*, SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed
5 in bronchial transient secretory cells. *The EMBO journal*, e105114 (Apr 4, 2020).
- 6 20. A. C. Walls *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
7 Glycoprotein. *Cell* **181**, 281 (Apr 16, 2020).
- 8 21. B. Coutard *et al.*, The spike glycoprotein of the new coronavirus 2019-nCoV contains a
9 furin-like cleavage site absent in CoV of the same clade. *Antiviral research* **176**, 104742
10 (Apr, 2020).
- 11 22. S. Matsuyama *et al.*, Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells.
12 *Proceedings of the National Academy of Sciences of the United States of America* **117**,
13 7001 (Mar 31, 2020).
- 14 23. R. Ueha, S. Ueha, K. Kondo, H. Nishijima, T. Yamasoba, Effects of Cigarette Smoke on
15 the Nasal Respiratory and Olfactory Mucosa in Allergic Rhinitis Mice. *Frontiers in*
16 *neuroscience* **14**, 126 (2020).
- 17 24. R. Ueha *et al.*, Reduction of Proliferating Olfactory Cells and Low Expression of

- 1 Extracellular Matrix Genes Are Hallmarks of the Aged Olfactory Mucosa. *Frontiers in*
2 *aging neuroscience* **10**, 86 (2018).
- 3 25. X. Zou *et al.*, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals
4 the potential risk of different human organs vulnerable to 2019-nCoV infection. *Frontiers*
5 *of medicine*, (Mar 12, 2020).
- 6 26. W. Sungnak *et al.*, SARS-CoV-2 entry factors are highly expressed in nasal epithelial
7 cells together with innate immune genes. *Nature medicine*, (Apr 23, 2020).
- 8 27. S. Bertram *et al.*, Influenza and SARS-coronavirus activating proteases TMPRSS2 and
9 HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. *PloS*
10 *one* **7**, e35876 (2012).
- 11 28. R. Ueha *et al.*, Laryngeal mucus hypersecretion is exacerbated after smoking cessation
12 and ameliorated by glucocorticoid administration. *Toxicology letters* **265**, 140 (Jan 4,
13 2017).
- 14 29. L. Pan *et al.*, Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in
15 Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. *The American journal*
16 *of gastroenterology* **115**, 766 (May, 2020).
- 17 30. T. Hummel *et al.*, Position paper on olfactory dysfunction. *Rhinology* **56**, 1 (Jan 31, 2016).

- 1 31. M. Okano, S. F. Takagi, Secretion and electrogenesis of the supporting cell in the
2 olfactory epithelium. *The Journal of physiology* **242**, 353 (Oct, 1974).
- 3 32. B. Branigan, P. Tadi, in *StatPearls*. (Treasure Island (FL), 2020).
- 4 33. C. Acevedo, K. Blanchard, J. Bacigalupo, C. Vergara, Possible ATP trafficking by ATP-
5 shuttles in the olfactory cilia and glucose transfer across the olfactory mucosa. *FEBS*
6 *letters* **593**, 601 (Mar, 2019).
- 7 34. D. G. Moulton, Dynamics of cell populations in the olfactory epithelium. *Annals of the*
8 *New York Academy of Sciences* **237**, 52 (Sep 27, 1974).
- 9 35. T. Hummel, Perspectives in Olfactory Loss Following Viral Infections of the Upper
10 Respiratory Tract. *Archives of otolaryngology--head & neck surgery* **126**, 802 (Jun, 2000).
- 11 36. L. A. Vaira, G. Salzano, G. Deiana, G. De Riu, Anosmia and Ageusia: Common Findings
12 in COVID-19 Patients. *The Laryngoscope*, (Apr 1, 2020).

13

14 **Funding:** This work was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research
15 [grant number 24791749, 16K20231] and by the Smoking Research Foundation (Tokyo, Japan).

16 **Author contributions:** R.U. developed the concept, designed and performed the experiments,
17 and wrote the draft of the manuscript. R.K. and S.S. designed and performed the experiments.


1 S.U. performed the experiments and wrote partially the draft of the manuscript. K.K, and T.Y.
2 developed the concept, designed the experiments and reviewed the manuscript. All authors
3 contributed to interpretation of the data and writing of the manuscript. **Competing interests:** The
4 authors declare that they have no competing interests. **Data and materials availability:** The
5 datasets generated for this study are available on request to the corresponding author.

6

7

1 Figure 1. Nose sagittal section and representative images of ACE2 staining in mouse kidney,
2 and TMPRSS2 and Furin staining in rat prostate.

3



4


5

6 **a:** Sagittal section of the rodent nose. The bars indicate the respiratory mucosal section (RM),
7 olfactory mucosal section (OM), and the olfactory bulb section (OB). **b:** Positive staining for ACE2
8 in the kidney, and TMPRSS2 and Furin in the prostate are shown. ACE2 positive cells are
9 observed in the brush boarder and the cytoplasm and nucleus of tubular cells. TMPRSS2
10 positive cells are observed in the cytoplasm and nucleus of acinar cells. Furin positive cells are
11 observed in the supranuclear cytoplasm (mainly Golgi apparatus) of acinar cells in the prostate
12 glands.

13

14

- 1 Figure 2: Representative images of mouse respiratory and olfactory mucosa stained with
- 2 antibodies against ACE2, TNPRSS2, and Furin.




3

1 **a** and **b**: The boxes in (a) indicate the parts of the respiratory mucosa (RM) that are shown at
2 higher magnification in (b) (a, 40x magnification; b, 400x magnification). In the RM area, the
3 respiratory epithelium (RE) was stained with ACE2 antibody. On the other hand, TMPRSS2 and
4 Furin were strongly stained in the cilia of the ciliated columnar RE and moderately stained in the
5 supranuclear cytoplasm of RE cells and subepithelial glands. **c** and **d**: In the olfactory mucosal
6 (OM) area, supporting cells (SPs, arrows), olfactory receptor neurons (ORNs), and basal cells
7 (BCs, arrow heads) were strongly stained with ACE2 antibody. TMPRSS2 expression was
8 negative in ORNs, moderately positive in SPs, and strongly positive in Bowman's glands (thick
9 black arrows) and the lamina propria. The olfactory nerve bundles showed weak co-expression
10 of ACE2 and TMPRSS2 (star marks). Furin was also expressed in SPs and Bowman's glands
11 (thick black arrows) The boxes in (c) indicate the parts of the OM that are shown at higher
12 magnification in (d) (c, 40x magnification; d, 400x magnification).

13

14

- 1 Figure 3: Representative images of mouse olfactory bulb stained with antibodies against ACE2,
- 2 TNPRSS2, and Furin; and gene expression levels in the nasal mucosa and olfactory bulb.




3

1 **a, b, c:** The olfactory bulb (OB) area. The boxes in (a) and (b) are shown at higher magnification
2 in (b) and (c), respectively (a, 40x magnification; b, 100x magnification; c, 400x magnification).
3 The OB parenchyma was weakly positive for ACE2, strongly positive for TMPRSS2, and
4 negative for Furin. While ACE2 positive cells could be recognized in the glomerular layer (GL),
5 mitral cell layer (MCL, arrow heads), and granule cell layer (GCL), those cells were negative for
6 TMPRSS2. Some mitral cells were positive for Furin (thick black arrows). TMPRSS2 was
7 strongly expressed in the cells of the OB core (star marks). **d:** Gene expression levels of *Ace2*,
8 *Tmprss2*, and *Furin* in the nasal mucosa and olfactory bulb are shown relative to the expression
9 of the endogenous control gene *Rps3* (encoding ribosomal protein S3). The graph is shown in
10 \log_{10} scale.

11

12

- 1 Figure 4: Representative images of human tissues stained with antibodies against ACE2,
- 2 TMPRSS2, and Furin.
- 3



4

5

1 **a** and **b**: In the olfactory mucosal area, the area of the olfactory epithelium was recognized using
2 PGP9.5 staining. PGP9.5⁺ ORNs mostly expressed ACE2, but not TMPRSS2 or Furin. There
3 was high expression of TMPRSS2 in the cytoplasm of the subepithelial glands. Furin was rarely
4 detected in human olfactory epithelium, but a weak expression was noted in the subepithelial
5 glands. The boxes in (a) are shown at higher magnification in (b) (a, 40x magnification; b, 400x
6 magnification). **c** - **f**: Representative images of the middle turbinate and inferior turbinate. The
7 boxes in (c) and (e) indicate the parts of the respiratory mucosa that are shown at higher
8 magnification in (d) and (f) (c, e, 40x magnification; d, f, 400x magnification). ACE2, TMPRSS2
9 and Furin protein expression was detected in the respiratory epithelium and subepithelial glands.
10 Specifically, TMPRSS2 expression was well detected.

11

1 Table 1. Protein expression levels of ACE2, TMPRSS2, and Furin in the respiratory mucosa,
2 olfactory mucosa, and olfactory bulb.

3

			ACE2	TMPRSS2	Furin
RM	RE	Nucleus	++	+	-
		Cytoplasm	+	+	+
	LP	Subepithelial Gland	+	++	++
OM	OE	Supporting cell	++	+	+
		Olfactory receptor neuron	++	-	-
		Basal cell	++	±	-
		Cytoplasm	-	+	+
	LP	Bowman's Gland	+	++	++
		Olfactory nerve bundle	+	+	-
OB	Glomerular layer		++	-	+
	Mitral cell layer		++	-	+
	Granule cell layer		++	-	-

4

5 Table 1 legend.

6 Both the respiratory mucosa (RM) and olfactory mucosa (OM) can be further subdivided into the
7 epithelium and the lamina propia (LP). In the respiratory epithelium (RE) several cells such as
8 ciliated columnar and goblet cells can be found, while the subepithelial glands are found in the
9 LP. The OM, which serves olfaction, consists of an olfactory epithelium (OE), which is composed
10 of olfactory receptor neurons (ORNs) and supporting and basal cells, and the LP, which contains
11 Bowman's glands and olfactory nerve bundles. Importantly, the degree of olfaction is closely
12 related to the number of mature olfactory receptor neurons (ORNs) in the OE. Moreover, the
13 olfactory system consists of peripheral compartments such as the OM, and central structures
14 such as the olfactory bulb (OB) and the piriform/entorhinal cortex. The olfactory bulb consists of
15 three layers; the glomerular, mitral cell, and granule cell layers.

16 +: mild expression, ++: moderate to strong expression, -: negative.

17